MXPA05007266A - Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno. - Google Patents

Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.

Info

Publication number
MXPA05007266A
MXPA05007266A MXPA05007266A MXPA05007266A MXPA05007266A MX PA05007266 A MXPA05007266 A MX PA05007266A MX PA05007266 A MXPA05007266 A MX PA05007266A MX PA05007266 A MXPA05007266 A MX PA05007266A MX PA05007266 A MXPA05007266 A MX PA05007266A
Authority
MX
Mexico
Prior art keywords
breast
drug
formulations
excipient
carrier
Prior art date
Application number
MXPA05007266A
Other languages
English (en)
Spanish (es)
Inventor
Peter Kevin Mays
Original Assignee
Femmepharma Holding Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Femmepharma Holding Co Inc filed Critical Femmepharma Holding Co Inc
Publication of MXPA05007266A publication Critical patent/MXPA05007266A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA05007266A 2003-01-02 2004-01-02 Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno. MXPA05007266A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43777803P 2003-01-02 2003-01-02
PCT/US2004/000023 WO2004060322A2 (en) 2003-01-02 2004-01-02 Pharmaceutical preparations for treatments of diseases and disorders of the breast

Publications (1)

Publication Number Publication Date
MXPA05007266A true MXPA05007266A (es) 2006-01-17

Family

ID=32713228

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007266A MXPA05007266A (es) 2003-01-02 2004-01-02 Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.

Country Status (7)

Country Link
US (1) US7812010B2 (https=)
EP (1) EP1578421A4 (https=)
JP (2) JP2006515026A (https=)
AU (1) AU2004203700B2 (https=)
CA (2) CA2764405A1 (https=)
MX (1) MXPA05007266A (https=)
WO (1) WO2004060322A2 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
JP2005513080A (ja) * 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド 薬物の膣送達
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9173836B2 (en) * 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
MXPA05007266A (es) 2003-01-02 2006-01-17 Femmepharma Holding Co Inc Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
GB2420281A (en) * 2004-11-22 2006-05-24 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of dermatological conditions
GB2421183A (en) * 2004-12-17 2006-06-21 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of skin cancers
CN101282646B (zh) * 2005-07-12 2013-03-27 Dmi生物科学公司 治疗疾病的方法和产品
EP1935413A4 (en) * 2005-10-12 2013-01-23 Kowa Co IONTOPHORESE PREPARATION FOR THE TREATMENT OF BREAST CANCER AND / OR MASTITIS
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP2104489A2 (en) * 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topical administration of danazol
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
JP2011135904A (ja) 2008-04-18 2011-07-14 Kowa Co 乳癌及び／又は乳腺炎治療用イオントフォレシス製剤
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
ES2523769T3 (es) 2009-06-22 2014-12-01 Ampio Pharmaceuticals, Inc. Procedimiento de tratamiento de enfermedades
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
EP2934546A4 (en) 2012-12-19 2016-06-22 Ampio Pharmaceuticals Inc METHOD OF DISEASE TREATMENT
MX377365B (es) 2016-09-08 2025-03-10 Journey Medical Corp Composiciones y métodos para tratar rosácea y acné.
WO2018093369A1 (en) * 2016-11-17 2018-05-24 Goren Ofer A Treatment of sexual dysfunction and for improved sexual quality of life
WO2021158517A1 (en) * 2020-02-03 2021-08-12 Curemast, Inc. Compositions and methods of use thereof for treatment of mastitis

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767824A (en) 1954-07-29 1957-02-06 Organon Labor Ltd Improvements in preparations for the treatment of the human skin
US3927216A (en) 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4081533A (en) 1976-09-01 1978-03-28 Regents Of The University Of California Method of reducing mammalian fertility and drugs therefor
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4291028A (en) 1977-12-30 1981-09-22 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4292315A (en) 1977-12-30 1981-09-29 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4286587A (en) 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4756907A (en) 1978-10-17 1988-07-12 Stolle Research & Development Corp. Active/passive immunization of the internal female reproductive organs
DE3214667C2 (de) 1982-04-21 1985-07-18 Akzo Gmbh, 5600 Wuppertal Zusammengesetzter Körper für die Langzeitabgabe von Wirkstoffen
US4524359A (en) 1982-07-23 1985-06-18 The United States Of America As Represented By The Secretary Of The Air Force Radar system for reducing angle tracking errors
US4588724A (en) 1982-12-10 1986-05-13 Greenway Frank L Iii Treatment for selective reduction of regional fat deposits
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4591496A (en) 1984-01-16 1986-05-27 Massachusetts Institute Of Technology Process for making systems for the controlled release of macromolecules
FR2558373B1 (fr) 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
NL8401912A (nl) 1984-06-15 1986-01-02 Tno Met aktieve stof beladen biodegradeerbare polymeersubstraten, geschikt voor het gecontroleerd afgeven van de aktieve stof door middel van een membraan.
JPS6163615A (ja) * 1984-09-05 1986-04-01 Shunichi Naito 消炎鎮痛剤
US4826830A (en) * 1985-07-31 1989-05-02 Jui Han Topical application of glyciphosphoramide
JPS62187415A (ja) * 1986-02-12 1987-08-15 Lion Corp 経皮吸収促進用組成物
US4762717A (en) 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US4919939A (en) 1986-04-29 1990-04-24 Pharmetrix Corporation Periodontal disease treatment system
US5057317A (en) 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4873092A (en) 1987-05-21 1989-10-10 Murata Kikai Kabushiki Kaisha Slow-releasing preparation
JP2590358B2 (ja) 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
US4945103A (en) 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
IT1235053B (it) * 1989-04-07 1992-06-17 Poli Ind Chimica Spa Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti.
US5130137A (en) 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
US5580857A (en) * 1989-12-12 1996-12-03 Oden; Per Use of gibberellins for the treatment of prostatitis
FR2663224B1 (fr) 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
US5091185A (en) 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5156851A (en) 1990-06-20 1992-10-20 Monsanto Company Coated veterinary implants
FR2669537B1 (fr) 1990-11-28 1993-02-19 Oreal Composition amincissante a base d'alpha-2-bloqueurs.
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU1442592A (en) 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
JPH0735335B2 (ja) 1991-02-28 1995-04-19 五十嵐 正雄 子宮内膜症の治療薬
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
ZA924811B (en) 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
DE69224809T2 (de) 1991-12-30 1998-07-09 Akzo Nobel Nv Thyroaktive Zusammensetzung mit kontrollierter Freigabe
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5614212A (en) * 1992-04-08 1997-03-25 International Medical Associates, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5482706A (en) 1992-04-17 1996-01-09 Takeda Chemical Industries, Ltd. Transmucosal therapeutic composition
CA2114968A1 (en) * 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5651976A (en) 1993-06-17 1997-07-29 The United States Of America As Represented By The Secretary Of The Navy Controlled release of active agents using inorganic tubules
GB9318641D0 (en) 1993-09-08 1993-10-27 Edko Trading Representation Compositions
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
NL9400410A (nl) 1994-03-16 1995-11-01 M D Ph D Willem Arthur Adriaan Intra-uterine anticonceptiemiddel.
US5482925A (en) 1994-03-17 1996-01-09 Comedicus Incorporated Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US5536499A (en) 1995-02-24 1996-07-16 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions for reducing or preventing signs of cellulite
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US5705170A (en) 1995-10-24 1998-01-06 Plantech International, Inc. Herbal cellulite treatments
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE59703511D1 (de) 1996-03-29 2001-06-13 S W Patentverwaltungs Ges M B Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der "cellulite"
US5778894A (en) 1996-04-18 1998-07-14 Elizabeth Arden Co. Method for reducing human body cellulite by treatment with pulsed electromagnetic energy
JP2001502302A (ja) 1996-09-19 2001-02-20 アメリカン・ホーム・プロダクツ・コーポレイション 尿失禁を治療する方法
US6416778B1 (en) * 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6071526A (en) 1997-03-27 2000-06-06 S.W. Patentverwertungs Ges M.B. H. Cosmetic or cosmetic product for firming and soothing the skin in particular in the case of cellulite
US6319913B1 (en) 1997-11-10 2001-11-20 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems
DE19830732B4 (de) * 1998-07-09 2008-11-13 Lts Lohmann Therapie-Systeme Ag Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung
ATE264093T1 (de) * 1998-07-16 2004-04-15 Aaron Tabor Sojazubereitungen und deren verwendung zur gesundheitsförderung
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
AU759016B2 (en) 1998-10-05 2003-04-03 Penn State Research Foundation, The Compositions and methods for enhancing receptor-mediated cellular internalization
JP2000143540A (ja) 1998-11-06 2000-05-23 Bristol Myers Squibb Co 非ステロイド系消炎鎮痛薬含有外用剤
AU5460800A (en) * 1999-06-02 2000-12-18 Aviana Biopharm Pharmaceutical transdermal compositions
US6358539B1 (en) 1999-08-20 2002-03-19 Howard Murad Pharmaceutical compositions for reducing the appearance of cellulite
WO2001019868A1 (en) * 1999-09-15 2001-03-22 Mogam Biotechnology Research Institute A novel angiogenesis inhibitor
WO2001051089A1 (de) * 2000-01-13 2001-07-19 Merck Patent Gmbh Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
US6436428B1 (en) 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
JP2003531157A (ja) 2000-04-26 2003-10-21 ワトソン ファーマシューティカルズ， インコーポレイテッド オキシブチニン治療に関連した有害な経験の最小化
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10054294A1 (de) 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
EP1249247B1 (en) 2001-03-30 2007-02-28 Chisso Corporation Pharmaceutical preparation for the treatment of gynecological diseases
DE10146541A1 (de) 2001-09-21 2003-04-17 Kade Pharma Fab Gmbh Arzneimittel auf Basis von Gestagenen zur dermalen Anwendung
WO2003028667A2 (en) 2001-10-04 2003-04-10 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
JP2005512995A (ja) 2001-11-09 2005-05-12 ファイザー ヘルス アーベー 不安定又は過活動膀胱を治療するための抗ムスカリン剤及びエストロゲンアゴニスト
JP2005513080A (ja) 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド 薬物の膣送達
US8476280B2 (en) 2002-05-09 2013-07-02 Versi Group, Llc Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
DE60327363D1 (de) 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
MXPA05007266A (es) 2003-01-02 2006-01-17 Femmepharma Holding Co Inc Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
US20050101579A1 (en) 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
EP2104489A2 (en) 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topical administration of danazol
AU2008259864C1 (en) 2007-05-30 2014-03-06 Microdose Therapeutx, Inc. Methods and compositions for administration of Oxybutynin

Also Published As

Publication number Publication date
AU2004203700B2 (en) 2007-06-21
CA2511995C (en) 2012-03-13
EP1578421A4 (en) 2009-04-22
WO2004060322A2 (en) 2004-07-22
EP1578421A2 (en) 2005-09-28
JP2006515026A (ja) 2006-05-18
WO2004060322A3 (en) 2005-04-07
AU2004203700A1 (en) 2004-07-22
US20040229813A1 (en) 2004-11-18
US7812010B2 (en) 2010-10-12
CA2511995A1 (en) 2004-07-22
JP2009280627A (ja) 2009-12-03
CA2764405A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
MXPA05007266A (es) Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
WO2008083158A3 (en) Topical administration of danazol
RU2004103074A (ru) Применение циклопамина при лечении псориаза
JP2002500180A5 (https=)
CN104940943A (zh) 喷雾用凝胶型皮肤·粘膜附着型制剂及使用它的给药系统
DE60100994D1 (de) Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
PT2210605T (pt) Formas de dosagem única diária de tróspio
EP1792927A4 (en) NEW BLOCK COPOLYMER, MICELLA PREPARATION AND ANTICROPHIDE CONTAINING THIS AS ACTIVE INGREDIENTS
PT2111868E (pt) Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos
US20210308096A1 (en) Composition for preventing or treating pruritus
WO2002028372A3 (en) Systemic delivery of compounds through non-invasive bladder administration
Zaigham et al. Recent trend in traditional medicine dosage form and present status of Unani and Ayurvedic medicine
WO2004017913A3 (en) Arginine silicate inositol complex and use thereof
CN104720131B (zh) 一种具有保健丰乳和防治乳腺疾病功能的胸罩
CN107530367A (zh) 口腔护理组合物
Marks et al. Pentoxifylline: wonder drug?
CN201783081U (zh) 一种新型内科用外敷中药治疗装置
Serrano et al. New galenic formulations of melatonin and therapeutic applications
CA3177251A1 (en) Superoxide dismutase compositions and methods
CN2512339Y (zh) 药磁石膏保健枕
Aleksandrovich et al. Development of a pharmacetical anticancer gel basedon doxorubicin and silicone nanotechnology
KR200370966Y1 (ko) 가발
RU2006110550A (ru) Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна
CN201216807Y (zh) 三位一体护理药垫
KR101900408B1 (ko) 가려움증의 예방 또는 치료용 조성물